Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.69 by 20.29 percent. This is a 46.6 percent decrease over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $215.400 million which missed the analyst consensus estimate of $225.227 million by 4.36 percent. This is a 16.60 percent increase over sales of $184.733 million the same period last year.